Trial Profile
ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation (The RAPID GENE Study).
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary) ; Clopidogrel
- Indications Acute coronary syndromes; Coronary artery disease; Coronary stent thrombosis
- Focus Pharmacodynamics; Pharmacogenomic
- Acronyms RAPID-GENE
- 03 Apr 2012 Results published in the Lancet.
- 22 Aug 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 22 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.